XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Provided By GlobeNewswire
Last update: Aug 13, 2025
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics.
Read more at globenewswire.comXOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (9/10/2025, 8:20:15 PM)
25.45
-0.1 (-0.39%)
NASDAQ:XOMA (9/10/2025, 8:20:15 PM)
36.58
-0.18 (-0.49%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (9/10/2025, 8:20:15 PM)
26.7
-0.3 (-1.11%)
Find more stocks in the Stock Screener
